Methods of treating diabetic neuropathic pain and post-surgical pain are provided. The methods include administering to an individual a therapeutically effective amount of a compound of Formula I (Compound 1). The method can be used to treat diabetic neuropathy arising from any type of nerve damage, and can also be used to treat post-surgical pain arising from any surgical procedure without the side effects associated with widely used analgesics such as opioids. Compound 1 can be formulated into many suitable dosage forms, including oral dosage forms such as tablets.

The present disclosure provides a macrocyclic compound of formula (I) (I), compositions and kits comprising this compound and their use for preventing or treating pain without inducing hypothermia, hypotension or ileum relaxation.

##STR00001##

The present invention relates to an acetaminophen injectable aqueous solution for use in the treatment or in the prevention of pain by spinal administration, wherein said acetaminophen injectable solution is supersaturated. In certain embodiments, the acetaminophen injectable aqueous solution is administered simultaneously, separately or sequentially with a local anaesthetic by spinal administration.

The invention provides stable, aqueous capsaicin injectable formulations, a unit dose containing such injectable formulations, medical kits, and methods for using such injectable formulations and unit doses to treat patients suffering from pain, such as osteoarthritic knee pain. The stable, aqueous capsaicin injectable formulations may contain, for example, capsaicin, a solubilizing agent (e.g., a polyethylene glycol ester of a (C.sub.15-C.sub.25) hydroxyalkanoic acid), an antioxidant, and water.

The invention provides stable, aqueous capsaicin injectable formulations, a unit dose containing such injectable formulations, medical kits, and methods for using such injectable formulations and unit doses to treat patients suffering from pain, such as osteoarthritic knee pain. The stable, aqueous capsaicin injectable formulations may contain, for example, capsaicin, a solubilizing agent (e.g., a polyethylene glycol ester of a (C.sub.15-C.sub.25) hydroxyalkanoic acid), an antioxidant, and water.

The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against α4β1 binding, and have high stability under gastrointestinal conditions.

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Disclosed herein are methods of administering resiniferatoxin (RTX) intravesically for treatment of bladder pain, and compositions for use in such methods.

The present invention relates to compounds of Formula (I) for use in the treatment of nervous system disorders and pain, wherein Formula (I) is:

##STR00001##

or a pharmaceutically acceptable salt or isomer thereof, wherein R is defined herein. The compounds are selective A.sub.1 adenosine receptor agonists with preferential action in the nervous system, with spared cardiovascular system and respiratory effects. The invention also relates to pharmaceutical compositions comprising the compounds.

The present invention relates to compounds of Formula (I) for use in the treatment of nervous system disorders and pain, wherein Formula (I) is:

##STR00001##

or a pharmaceutically acceptable salt or isomer thereof, wherein R is defined herein. The compounds are selective A.sub.1 adenosine receptor agonists with preferential action in the nervous system, with spared cardiovascular system and respiratory effects. The invention also relates to pharmaceutical compositions comprising the compounds.